Product Description: Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 4, 2022.
CAS Number: 2723442-10-0
Molecular Weight: N/A
Compound Purity: 97.78
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Others